Your browser doesn't support javascript.
Pre-exposure Prophylaxis With Various Doses of Hydroxychloroquine Among Healthcare Personnel With High-Risk Exposure to COVID-19: A Randomized Controlled Trial.
Syed, Fibhaa; Hassan, Muhammad; Arif, Mohammad Ali; Batool, Sadia; Niazi, Rauf; Laila, Ume E; Ashraf, Sadia; Arshad, Junaid.
  • Syed F; Internal Medicine, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, PAK.
  • Hassan M; Neurology, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, PAK.
  • Arif MA; Internal Medicine, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, PAK.
  • Batool S; Internal Medicine, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, PAK.
  • Niazi R; Internal Medicine, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, PAK.
  • Laila UE; Internal Medicine, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, PAK.
  • Ashraf S; Internal Medicine, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, PAK.
  • Arshad J; Cardiology, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, PAK.
Cureus ; 13(12): e20572, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1662861
ABSTRACT
Objective This trial aimed to evaluate the safety and efficacy of pre-exposure prophylaxis (PrEP) with various hydroxychloroquine (HCQ) doses against a placebo among healthcare personnel (HCP) with high-risk exposure to coronavirus disease 2019 (COVID 19). Methods A phase II, randomized, placebo-controlled trial was conducted including 200 subjects with no active or past severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (antibody testing and reverse transcription-polymerase chain reaction (RT-PCR) were taken at the time of enrollment). Subjects of experimental groups one to three received HCQ in various doses and the control group received a placebo. The study outcomes in terms of safety and efficacy were monitored. Participants exhibiting COVID-19 symptoms were tested for SARS-CoV-2 during the study and by the end of week 12 with RT-PCR or serology testing (COVID-19 IgM/IgG antibody testing). Results Out of the total participants, 146 reported exposure to a confirmed COVID-19 case in the first month, and 192 were exposed by week 12 of the study. Moreover, the precautionary use of personal protective equipment (PPE) significantly varied; initially more than 80% of the exposed HCPs were not ensuring PPE being used by the patients treated by them, which gradually developed over time. Mild treatment-related side effects were observed among the interventional and placebo arm patients. There was no significant clinical benefit of PrEP with HCQ as compared to placebo (p>0.05). Conclusion It is concluded that the PrEP HCQ does not significantly prevent COVID-19 among high-risk HCPs.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Cureus Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Journal: Cureus Year: 2021 Document Type: Article